Factors related to quality of life in patients with cirrhosis and ascites: relevance of serum sodium concentration and leg edema.
about
Usefulness of portal vein pressure for predicting the effects of tolvaptan in cirrhotic patientsHyponatremia in cirrhosis: pathophysiology and managementThe treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites: a meta-analysis of randomized controlled trials.Hyponatremia and Hepatorenal SyndromeMultidisciplinary management of patients with cirrhosis: a need for care coordinationDifferential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis.Long-term quality of life of liver transplant recipients beyond 60 years of age.Etiology and complications of liver cirrhosis in children:report of a single center from southern iran.Quality of life in cirrhosis.Low-dose tolvaptan for the treatment of dilutional hyponatremia in cirrhosis: a case report and literature review.Pathophysiology and management of hepatic encephalopathy 2014 update: Ammonia toxicity and hyponatremia.The impact on patients of a nurse-led clinical service in gastroenterology.Effects of alfapump™ system on kidney and circulatory function in patients with cirrhosis and refractory ascites.The Changing Role of Sodium Management in Cirrhosis.Hyponatremia - unfavourable prognostic factor in hepatic cirrhosis.Electrolyte and Acid-Base Disturbances in End-Stage Liver Disease: A Physiopathological Approach.Ascites, refractory ascites and hyponatremia in cirrhosis.Management of ascites and hepatorenal syndrome.Factors associated with medication adherence in patients living with cirrhosis.Potential Effectiveness of Tolvaptan to Improve Ascites Unresponsive to Standard Diuretics and Overall Survival in Patients with Decompensated Liver Cirrhosis.Efficacy of tolvaptan in patients with refractory ascites in a clinical settingEffectiveness of tolvaptan monotherapy and low-dose furosemide/tolvaptan combination therapy for hepatoprotection and diuresis in a rat cirrhotic modelHyponatraemia and cirrhosis.Tolvaptan for improvement of hepatic edema: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial.Predictors of quality of life in patients evaluated for liver transplantation.Editorial: alfapump-an alternative to large-volume paracentesis for patients with refractory ascites?Factors contributing to the development of overt encephalopathy in liver cirrhosis patients.Hyponatraemia in cancer: association with type of cancer and mortality.Effectiveness and safety of tolvaptan in liver cirrhosis patients with edema: Interim results of post-marketing surveillance of tolvaptan in liver cirrhosis (START study).Urinary excretion of the water channel aquaporin 2 correlated with the pharmacological effect of tolvaptan in cirrhotic patients with ascites.CD34(+) cell therapy is safe and effective in slowing the decline of hepatic reserve function in patients with decompensated liver cirrhosis.Development and predictive validity of the cirrhosis-associated ascites symptom scale: A cohort study of 103 patients.
P2860
Q24658600-151F567D-F31B-4069-9EEA-7E40DFAD5FA9Q27027861-49CA325C-5D4D-49E4-9A71-4C482E3612D3Q35657152-14D1DC94-6B6D-4524-8981-1CEEA65B32E7Q36812531-BF02941E-C568-4D7D-8FFB-6DF048D60428Q36816778-E6B00B4A-1FA4-423D-B082-1C59DC446045Q37107261-20367A2E-2EB3-4A5A-A071-E906DBDA8FC8Q37300605-8EC59993-B37A-4736-BB31-7A871860B34BQ37708319-222A52CC-2453-41DC-AF3C-3092A2E6D8ECQ38068356-5570B836-20E6-4730-BAA0-129B24ACBED4Q38266482-D7977C48-023A-4B61-B0DB-A1FFEB8EAC82Q38325703-2C88B907-65F2-4CD5-865E-FBEADC99AB03Q38658210-180C2AC5-CB4E-4B8F-8F18-4090C78B604CQ38743020-8EC8AA55-A8AB-48EC-9938-F1D93EF8BE43Q38796241-D04CE469-DABF-4965-B7F1-403301A4377FQ39046475-7C8660C0-78C5-46C8-9666-A019B7DF367DQ39304722-62638ABB-A546-462A-86F4-DF8F3272F357Q39323841-AE5BC93F-775E-4C78-8977-1C56BBF3C039Q40081708-41F582ED-F28E-49BE-90C3-C3BD1D3AF087Q40106356-A1D6B1B0-E292-4756-947B-B8AE45929D27Q40654657-3803B4F7-6F55-4643-87DC-0681EF3846EEQ40771170-E25D3C95-3A08-4582-B188-B502199EE495Q41110019-3A2D87D2-060E-4E83-952B-81CAD5AA187EQ41946824-A5F6655E-AB5F-4DD2-B42C-D3F90CE6A316Q45107672-D73EB70B-B0CF-42FC-BA1D-A96BA0F56715Q48070110-212BFD23-D679-4030-A1C3-1A067DB12425Q48144809-0820A887-AB4B-4DE3-9C44-21C6975DD35EQ48651542-87E0BC16-7FA0-4E09-B182-B7912AF92516Q48878196-AC8BE2A7-2EF3-4072-AC70-7CB7CD8A2ED0Q50221452-BFA7CB71-C471-4ED9-BF65-99B2EB34C484Q50277167-5A5BB18A-BF9D-43B3-AF82-7E34DD5B110EQ53057906-AC8CD1F8-4D60-4E7F-903C-3B0ECD1F274AQ55078767-59AACBD8-33F6-4125-A12E-55096E12541C
P2860
Factors related to quality of life in patients with cirrhosis and ascites: relevance of serum sodium concentration and leg edema.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Factors related to quality of ...... m concentration and leg edema.
@en
Factors related to quality of ...... m concentration and leg edema.
@nl
type
label
Factors related to quality of ...... m concentration and leg edema.
@en
Factors related to quality of ...... m concentration and leg edema.
@nl
prefLabel
Factors related to quality of ...... m concentration and leg edema.
@en
Factors related to quality of ...... m concentration and leg edema.
@nl
P2093
P50
P1476
Factors related to quality of ...... um concentration and leg edema
@en
P2093
Fanny Turón
Hugh Watson
Marco Pavesi
Mónica Guevara
Rogelio Barreto
P304
P356
10.1016/J.JHEP.2012.07.020
P577
2012-07-20T00:00:00Z